AI/ML Innovations Inc. (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) announced on September 29, 2026 that its wholly owned subsidiary, NeuralCloud Solutions Inc., has entered a strategic partnership with Toronto-based RKS Medical Technologies to advance clinical pilot deployments of its CardioYield™ software platform paired with RKS Medical's myPatch® Holter monitoring hardware. The collaboration targets pre-regulatory clearance pilot evaluations at Ontario clinics, with potential expansion to additional Canadian provinces. Investors may be watching closely given the partnership represents a key step in NeuralCloud's strategy to build a network of clinical pilot sites ahead of future commercial deployment.

Key Points

  • AI/ML Innovations Inc. (CSE: AIML; OTCQB: AIMLF; FWB: 42FB)
  • NeuralCloud has entered a strategic partnership with RKS Medical Technologies to conduct pre-regulatory clearance clinical pilots of CardioYield™ with myPatch® Holter devices
  • Initial pilot focus is Ontario clinics; AIML also extended 44,189,076 share purchase warrants to new expiry dates of November 1, 2029 and November 26, 2029 at an exercise price of $0.15 per share
  • CardioYield™ has not received Health Canada or FDA clearance and is not currently authorised for diagnostic use

CardioYield™ and myPatch® Integration Creates End-to-End Holter Monitoring Workflow

The partnership pairs RKS Medical's myPatch®SL wireless Holter recorder — a lightweight, waterproof device offering up to three channels of continuous ECG and compatibility with major Holter analysis systems — with NeuralCloud's CardioYield™ platform. CardioYield™ is powered by MaxYield™, NeuralCloud's proprietary ECG signal-processing engine designed to improve signal quality, isolate key waveform components including P waves, QRS complexes, and T waves, and generate structured Holter reports. The combined workflow is intended to support enhanced ECG review, automated waveform analysis, and improved reporting efficiency for Canadian clinics.

Ontario Clinical Pilot Structure and Pre-Regulatory Evaluation Framework

Under the agreement, RKS Medical is expected to identify and introduce clinic sites currently using or evaluating myPatch® technology, while NeuralCloud will run the CardioYield™ pilots directly and manage clinical integration. Pilots are designed to use de-identified ECG recordings from normal patient care, routed through both existing clinic workflows and CardioYield™ simultaneously for side-by-side comparison. Evaluation metrics are expected to include physician-ready report agreement, false positive and false negative rates, technician edit time, turnaround time, signal-quality scoring, and rhythm category detection. Qualified healthcare professionals will retain responsibility for all official reports and patient-care decisions throughout.

AIML Extends November 2024 Financing Warrants by Five Years

Alongside the partnership announcement, AIML disclosed that it has approved the extension of 44,189,076 existing share purchase warrants originally issued on November 1, 2024 and November 26, 2024 as part of a non-brokered private placement at $0.065 per unit. Each warrant remains exercisable to acquire one common share at $0.15. The new expiry dates are November 1, 2029 and November 26, 2029, representing five years from the applicable original issuance dates. The company noted that amendments to broker warrants are not permitted under CSE Policy 6.7(3) and are therefore excluded from this extension. All other warrant terms remain unchanged.